This trial evaluates the effect of a supportive oncology care at home intervention in improving overall care for patients with cancer receiving definitive cancer treatment. Patients receiving treatment for cancer often require multiple visits for their care and may experience symptoms and side effects related to the cancer and treatment for their cancer. The supportive oncology care at home intervention consists of remote monitoring and home-based care. Remote monitoring is a way of monitoring patients outside of conventional clinical settings (e.g. in the home) that often utilizes technology to increase access to care. This trial may help doctors determine if remote monitoring and home-based care improves the overall care of patients receiving cancer treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04544046.
PRIMARY OBJECTIVES:
I. To determine the effect of the supportive oncology care at home intervention on unplanned admission to the hospital or emergency department (ED) in patients receiving definitive treatment for their cancer.
II. To assess the impact of the supportive oncology care at home intervention on treatment interruptions in patients receiving definitive treatment for their cancer.
III. To evaluate the effect of the supportive oncology care at home intervention on patient-reported outcomes (e.g. quality of life [QOL], symptom burden, psychological distress, physical function, and care satisfaction) in patients receiving definitive treatment for their cancer.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive standard oncology care and attend regular clinic visits.
GROUP II: Patients receive supportive oncology care at home during chemotherapy treatment for patients with pancreatic, gastroesophageal, rectal cancer, and aggressive non-Hodgkin lymphoma or during chemotherapy treatment and until 30 days after stopping treatment for patients with head and neck cancer.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorPatrick Connor Johnson
